Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 3.01 (Notice of Delisting), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.02 (Departure/Election of Directors or Officers). Apogee terminated its 2023 Equity Incentive Plan effective at the transaction’s Effective Time.
- This filing includes Item 3.01, an item that often signal trouble.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Apogee terminated its 2023 Equity Incentive Plan effective at the transaction’s Effective Time
- Apogee also terminated its 2023 Employee Stock Purchase Plan
- Termination ends these equity-based compensation and employee stock purchase programs; transaction context determines shareholder impact
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger completed with full board replacement by Merger Sub directors, signaling a new control and governance structure
- All existing executive officers ceased serving at the Effective Time, creating immediate leadership transition risk
- September 1, 2026 agreements provide excise-tax gross-ups for merger-related payments under Internal Revenue Code Section 4999
- Aggregate gross-up payments for participating service providers capped at $12,500,000, limiting potential transaction-related obligations
Item 3.01 · Notice of Delisting
- Merger completion ended APGE common shareholders’ equity ownership at the effective time
- Former shareholders retain only the right to receive merger consideration, subject to tax withholding
- APGE shares no longer carry voting, dividend, or other stockholder rights after the merger
Item 5.02 · Departure/Election of Directors or Officers
- Amended certificate of incorporation and bylaws became effective at merger closing
- Governance framework reset in connection with the merger
- Investor impact depends on merger-specific voting, board, and shareholder-rights provisions in Exhibits 3.1 and 3.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.